<DOC>
	<DOCNO>NCT01439373</DOCNO>
	<brief_summary>GSK2336805 hepatitis C virus ( HCV ) NS5A inhibitor develop treatment chronic hepatitis C ( CHC ) . This study ass safety , antiviral activity , pharmacokinetics GSK2336805 alone combination peginterferon alfa 2a ribavirin subject chronic hepatitis C ( CHC ) .</brief_summary>
	<brief_title>Safety , Antiviral Activity , Pharmacokinetics GSK2336805 With Peginterferon Ribavirin Chronic Hepatitis C Subjects</brief_title>
	<detailed_description>HCV infection major public health problem globally leading cause chronic liver disease . New medication need well tolerate offer great chance achieve sustained viral clearance compare currently available therapy . GSK2336805 HCV NS5A inhibitor develop treatment subject CHC . This Phase II , double blind , randomize , placebo-controlled study ass safety , antiviral activity , pharmacokinetics GSK2336805 alone combination peginterferon alfa 2a ribavirin subject CHC . Subjects randomly allocate 2:1 basis GSK2336805 match placebo stratify IL28B status HCV viral genotype ( genotype 1 4 ) . The study consist 2 part . In Part 1 , GSK2336805 match placebo give single-dose monotherapy ( Day 1 ) . In Part 2 , GSK2336805 match placebo co-administered peginterferon alfa-2a ribavirin 4 week treatment ( Days 2 28 ) . After completion Part 2 , GSK2336805/matching placebo discontinue subject offer continued standard-of-care anti-HCV therapy .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Key Documented chronic genotype 1 genotype 4 HCV infection Na√Øve HCV antiviral treatment ( ) Agree IL28B genotyping A body mass index &gt; 18 kg/m2 exceed 36 kg/m2 Liver biopsy obtain within 3 year ( 36 calendar month ) prior Day 1 visit , fibrosis classification noncirrhotic . If recent ( &lt; 36 month ) liver biopsy available , study qualify biopsy must perform prior Baseline ( Day 1 ) All fertile male female must use two form effective contraception treatment 24 week treatment end Otherwise healthy determine medical history , physical examination , ECG finding , clinical laboratory measurement perform Screening Key Positive test Screening hepatitis B surface antigen ( HBsAg ) antihuman immunodeficiency virus antibody History clinically significant chronic liver disease History ascites , variceal hemorrhage , hepatic encephalopathy , condition consistent decompensated liver disease Positive result urine screen drug abuse test Screening ( unless use medical treatment , e.g. , prescription ) History alcohol/drug abuse dependence within 6 month study start ( unless participate controlled rehabilitation program ) Screening ECG correct QT interval value great 450 m and/or clinically significant ECG find A personal family history Torsade de Pointes finding Pregnant nursing woman Males female partner pregnant Abnormal hematological biochemical parameter specify protocol History major organ transplantation exist functional graft Thyroid dysfunction adequately controlled Subjects history suicide attempt hospitalization depression past 5 year and/or current ( within 6 month ) severe poorly control psychiatric disorder History current evidence immunologic disorder ; pulmonary , cardiac , pulmonary disease ; seizure disorder ; cancer history malignancy opinion investigator make subject unsuitable study Participation clinical study investigational drug , biologic , device within 3 month prior first dose administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>chronic hepatitis C</keyword>
	<keyword>NS5A inhibitor</keyword>
	<keyword>ribavirin</keyword>
	<keyword>pegylated interferon</keyword>
	<keyword>GSK2336805</keyword>
</DOC>